Barclays PLC Nektar Therapeutics Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Nektar Therapeutics stock. As of the latest transaction made, Barclays PLC holds 358,294 shares of NKTR stock, worth $383,374. This represents 0.0% of its overall portfolio holdings.

Number of Shares

358,294

Previous 182,698 96.11%

Holding current value

$383,374

Previous $227,000 105.29%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$1.11 - $1.48 $194,911 - $259,882	175,596 Added 96.11%	358,294 $466,000
Q2 2024 Aug 14, 2024	SELL	$0.9 - $1.83 $351,249 - $714,206	-390,277 Reduced 68.11%	182,698 $227,000
Q1 2024 May 15, 2024	BUY	$0.49 - $0.96 $2,485 - $4,870	5,073 Added 0.89%	572,975 $535,000
Q4 2023 Feb 15, 2024	BUY	$0.42 - $0.57 $141,985 - $192,694	338,061 Added 147.08%	567,902 $321,000
Q3 2023 Nov 07, 2023	BUY	$0.51 - $1.05 $87,979 - $181,134	172,509 Added 300.89%	229,841 $137,000
Q2 2023 Aug 03, 2023	SELL	$0.53 - $1.03 $50,573 - $98,284	-95,422 Reduced 62.47%	57,332 $33,000
Q1 2023 May 04, 2023	SELL	$0.64 - $3.15 $7,133 - $35,109	-11,146 Reduced 6.8%	152,754 $108,000
Q4 2022 Feb 13, 2023	BUY	$2.03 - $4.28 $39,475 - $83,228	19,446 Added 13.46%	163,900 $372,000
Q3 2022 Nov 03, 2022	SELL	$3.04 - $5.14 $337,689 - $570,961	-111,082 Reduced 43.47%	144,454 $463,000
Q2 2022 Aug 12, 2022	BUY	$3.17 - $6.17 $201,507 - $392,208	63,567 Added 33.11%	255,536 $971,000
Q1 2022 May 16, 2022	BUY	$4.16 - $13.72 $472,642 - $1.56 Million	113,616 Added 145.01%	191,969 $1.04 Million
Q4 2021 Feb 14, 2022	SELL	$10.83 - $18.41 $665,622 - $1.13 Million	-61,461 Reduced 43.96%	78,353 $1.06 Million
Q3 2021 Nov 09, 2021	SELL	$13.07 - $18.84 $909,005 - $1.31 Million	-69,549 Reduced 33.22%	139,814 $2.51 Million
Q2 2021 Aug 13, 2021	BUY	$16.52 - $20.4 $3.17 Million - $3.91 Million	191,836 Added 1094.52%	209,363 $3.59 Million
Q1 2021 May 13, 2021	SELL	$16.56 - $25.46 $310,119 - $476,789	-18,727 Reduced 51.65%	17,527 $350,000
Q4 2020 Feb 11, 2021	SELL	$15.77 - $19.03 $2.69 Million - $3.24 Million	-170,356 Reduced 82.45%	36,254 $616,000
Q3 2020 Nov 12, 2020	SELL	$16.59 - $24.79 $695,038 - $1.04 Million	-41,895 Reduced 16.86%	206,610 $3.43 Million
Q2 2020 Aug 12, 2020	SELL	$16.86 - $23.44 $1.7 Million - $2.37 Million	-100,970 Reduced 28.89%	248,505 $5.76 Million
Q1 2020 May 13, 2020	BUY	$14.47 - $27.96 $2.7 Million - $5.23 Million	186,915 Added 114.98%	349,475 $6.24 Million
Q4 2019 Feb 10, 2020	SELL	$15.87 - $23.12 $5.29 Million - $7.71 Million	-333,434 Reduced 67.23%	162,560 $3.51 Million
Q3 2019 Nov 14, 2019	BUY	$16.91 - $36.27 $4.15 Million - $8.9 Million	245,477 Added 97.99%	495,994 $9.03 Million
Q2 2019 Aug 14, 2019	BUY	$31.0 - $36.3 $918,840 - $1.08 Million	29,640 Added 13.42%	250,517 $8.91 Million
Q1 2019 May 15, 2019	BUY	$31.58 - $46.35 $133,299 - $195,643	4,221 Added 1.95%	220,877 $7.42 Million
Q4 2018 Feb 14, 2019	SELL	$30.43 - $56.65 $2.21 Million - $4.12 Million	-72,700 Reduced 25.12%	216,656 $7.12 Million
Q3 2018 Nov 14, 2018	SELL	$46.46 - $68.49 $5.3 Million - $7.82 Million	-114,147 Reduced 28.29%	289,356 $17.6 Million
Q2 2018 Aug 14, 2018	BUY	$46.25 - $104.45 $5.53 Million - $12.5 Million	119,670 Added 42.16%	403,503 $19.7 Million
Q1 2018 May 15, 2018	SELL	$57.4 - $108.44 $6.08 Million - $11.5 Million	-105,979 Reduced 27.19%	283,833 $30.2 Million
Q4 2017 Feb 14, 2018	BUY	$23.02 - $60.5 $3.63 Million - $9.55 Million	157,880 Added 68.07%	389,812 $23.3 Million
Q3 2017 Nov 14, 2017	BUY	$17.79 - $24.0 $4.13 Million - $5.57 Million	231,932	231,932 $5.57 Million

Others Institutions Holding NKTR

# of Institutions

147

Shares Held

139M

Call Options Held

32.6K

Put Options Held

14.1K

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $201M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account